Overview
Study: Elkin, Oh et al., NPJ Genomic Medicine, 2021. Memorial Sloan Kettering Cancer Center, with Stony Brook University and the Institute for Advanced Study.
Cohort: 45 patients with high-grade serous ovarian cancer treated with immune checkpoint inhibitors, one tumor/normal pair each. The paper describes all 45 as high-grade serous; the release classifies 42 that way, plus 1 low-grade serous, 1 squamous cell carcinoma and 1 poorly differentiated carcinoma.
Platform: Targeted tumor/normal sequencing with MSK-IMPACT: mutations, copy-number alterations and structural variants. The paper also drew copy-number data from whole-exome sequencing.
Findings: The authors placed each patient's gene-level copy-number alterations on a protein–protein interaction network and used a network-curvature measure to split patients into higher- and lower-risk groups. Overall survival from the start of immunotherapy differed between the groups (log-rank p = 0.00047).
Clinical annotations: Overall survival, MSI, tumor mutational burden, tumor purity, sample type and metastatic site.